Pilot Trial Data on Cytokine Response to Spinal Manipulation in Multiple Sclerosis

21 participants with relapsing-remitting multiple sclerosis were randomized into spinal manipulation or sham groups for a four-week pilot trial. The dataset contains measurements for 21 inflammatory biomarkers, 3 neurodegenerative biomarkers, and 12 clinical outcomes collected at five timepoints. Author Murdi S. Alanazi published this data in 2026 from a trial registered in 2021.

Use Cases

• Analyze effect size (Cohen's d) for specific cytokines like IL-8, IL-17A, GM-CSF, MIP-1β, IFNγ, and Fractalkine across multiple post-intervention timepoints.
• Model changes in neurodegenerative biomarker t-tau levels against intervention group assignment and clinical outcome scores.
• Compare change scores from baseline for 12 clinical and performance-based outcomes between the spinal manipulation and sham-control groups.
• Examine biomarker trajectories across five collection timepoints (T0 to T4) to identify immediate versus delayed inflammatory responses.

Strengths

• Includes data for 21 inflammatory biomarkers, 3 neurodegenerative biomarkers, and 12 clinical outcomes per participant.
• Data collected at five standardized timepoints, enabling longitudinal analysis of intervention effects.

Limitations

• Very small sample size of 21 total participants limits statistical power and generalizability.
• Pilot study design primarily informs future research; most clinical outcomes showed small effect sizes below relevance thresholds.

Provenance

Source

figshare, authored by Murdi S. Alanazi.

Collection Method

Data from a pilot randomized, sham-controlled clinical trial (NCT04972929).

Time Range

Trial intervention period covered four weeks, with data collection at specific timepoints within that period.

Freshness

Data reflects a trial registered in 2021, with results published in 2026.

Geography

null